Dr.OINDRILA DAS

DR. SAYANTAN GHOSH, DR. SNEHA JAIN, Dr.Mondal Lakshmi Kanta

Abstract

Purpose:Irvine-Gass syndrome(IGS) being an important cause of low vision post-cataract surgery and the affordability and accessibility of triamcinolone acetonide being better than Ranibizumab, our aim is to compare the efficacy and safety of posterior subtenon triamcinolone acetonide(PSTA) with intravitreal Ranibizumab(IVR) in treating IGS.

Method:In this prospective study conducted from April 2019 to March 2020 one group consisting 54 eyes with IGS received 2 doses of PSTA and the other group of 60 eyes with IGS received 3 doses of IVR at an interval of 1 month.Evaluation of BCVA,central macular thickness, and intraocular pressure before, at 3 months and at 6 months after injections was done.

Result:On follow up, eyes receiving IVR showed better visual recovery compared to those receiving PSTA. Significant elevation of IOP was noted at 3 months in the PSTA group.

Conclusion:IVR had better early and sustained outcome in respect to safety and efficacy in treating IGS compared to PSTA.